ARG54898

anti-MDM2 phospho (Ser166) antibody

anti-MDM2 phospho (Ser166) antibody for ICC/IF,Western blot and Human

Cancer antibody; Cell Biology and Cellular Response antibody; Gene Regulation antibody

Overview

Product Description Rabbit Polyclonal antibody recognizes MDM2 phospho (Ser166)
Tested Reactivity Hu
Tested Application ICC/IF, WB
Host Rabbit
Clonality Polyclonal
Isotype IgG
Target Name MDM2
Antigen Species Human
Immunogen Phosphospecific peptide around Ser166 of Human MDM2 (NP_001138809.1)
Conjugation Un-conjugated
Alternate Names EC 6.3.2.-; Double minute 2 protein; p53-binding protein Mdm2; hdm2; Oncoprotein Mdm2; HDMX; ACTFS; E3 ubiquitin-protein ligase Mdm2; Hdm2

Application Instructions

Application Suggestion
Tested Application Dilution
ICC/IF1:50 - 1:100
WB1:500 - 1:1000
Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.
Positive Control 293 cells treated by Hydroxyurea.

Properties

Form Liquid
Purification Affinity purification with immunogen.
Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol
Preservative 0.02% Sodium azide
Stabilizer 50% Glycerol
Storage Instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use.
Note For laboratory research only, not for drug, diagnostic or other use.

Bioinformation

Database Links

GeneID: 4193 Human MDM2

Swiss-port # Q00987 Human E3 ubiquitin-protein ligase Mdm2

Gene Symbol MDM2
Gene Full Name MDM2 proto-oncogene, E3 ubiquitin protein ligase
Background This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in a multitude of transcript variants, many of which may be expressed only in tumor cells. [provided by RefSeq, Jun 2013]
Function E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation. [UniProt]
Research Area Cancer antibody; Cell Biology and Cellular Response antibody; Gene Regulation antibody
Calculated MW 55 kDa
PTM Phosphorylation on Ser-166 by SGK1 activates ubiquitination of p53/TP53. Phosphorylated at multiple sites near the RING domain by ATM upon DNA damage; this prevents oligomerization and E3 ligase processivity and impedes constitutive p53/TP53 degradation.
Autoubiquitination leads to proteasomal degradation; resulting in p53/TP53 activation it may be regulated by SFN. Also ubiquitinated by TRIM13. Deubiquitinated by USP2 leads to its accumulation and increases deubiquitination and degradation of p53/TP53. Deubiquitinated by USP7 leading to its stabilization.